{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:31:16Z","timestamp":1789579876963,"version":"build-2803163510"},"reference-count":28,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1 P50 CA217674-01A1"],"award-info":[{"award-number":["1 P50 CA217674-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,10,4]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>Blockade of the immune checkpoints programmed death-1 (PD-1) and cytotoxic lymphocyte antigen 4 has improved outcomes for patients with hepatocellular carcinoma (HCC), yet most still fail to achieve objective clinical benefit. MET plays key roles in both HCC tumorigenesis and immunosuppressive conditioning; however, inhibition of MET causes upregulation of PD-ligand 1 (PD-L1) suggesting the use of these inhibitors in the context of PD-1 blockade. We sought to investigate across the Hepa1-6, HCA-1 and diethylnitrosamine (DEN) models of HCC whether the combination of more specific type I versus more pleiotropic type II MET inhibitors would confer superior outcomes in combination with PD-1 blockade. While MET inhibition demonstrated cooperativity with \u03b1PD-1 across all three models, the type I MET inhibitor capmatinib showed optimal activity in combination and statistically significantly outperformed the combination with the type II inhibitor cabozantinib in the \u03b1PD-1 refractory DEN model. In both HCA-1 and DEN HCC, the capmatinib and \u03b1PD-1 combination enhanced CD8 T cell frequency and activation state while limiting intratumoral myeloid immune suppression. In vitro studies of antigen-specific T cell activation reveal significantly less inhibition of effector cytokine production and proliferation by capmatinib versus by type II or type III MET inhibitors. These findings suggest significant potential for clinical HCC combination studies of type I MET inhibitors and PD-1 blockade where prior trials using type II inhibitors have yielded limited benefit.<\/jats:p>","DOI":"10.1136\/jitc-2024-009690","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T11:38:16Z","timestamp":1730288296000},"page":"e009690","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct02323126","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02795429","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ricardo","family":"DeAzevedo","sequence":"first","affiliation":[{"name":"Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Steiner","sequence":"additional","affiliation":[{"name":"Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Immunology Program, The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Broderick X","family":"Turner","sequence":"additional","affiliation":[{"name":"Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Immunology Program, The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Immunology Program, The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherwin","family":"Newton","sequence":"additional","affiliation":[{"name":"Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Carlsbad, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Fleming","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Carlsbad, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Tolentino","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Carlsbad, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed O","family":"Kaseb","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4996-7207","authenticated-orcid":false,"given":"Michael A","family":"Curran","sequence":"additional","affiliation":[{"name":"Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"2025100305590775000_12.10.e009690.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3205"},{"key":"2025100305590775000_12.10.e009690.2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2791"},{"key":"2025100305590775000_12.10.e009690.3","doi-asserted-by":"crossref","first-page":"103602","DOI":"10.1016\/j.critrevonc.2022.103602","article-title":"The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences","volume":"172","author":"Fogli","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025100305590775000_12.10.e009690.4","doi-asserted-by":"crossref","DOI":"10.1177\/1758835921992976","article-title":"Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer","volume":"13","author":"Hong","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"2025100305590775000_12.10.e009690.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.252"},{"key":"2025100305590775000_12.10.e009690.6","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1200\/JCO.22.00972","article-title":"Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial","volume":"41","author":"Yau","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100305590775000_12.10.e009690.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00326-6"},{"key":"2025100305590775000_12.10.e009690.8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.immuni.2017.09.012","article-title":"Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy","volume":"47","author":"Glodde","year":"2017","journal-title":"Immunity"},{"key":"2025100305590775000_12.10.e009690.9","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1158\/1078-0432.CCR-21-2517","article-title":"Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma","volume":"28","author":"Esteban-Fabr\u00f3","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100305590775000_12.10.e009690.10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-07153-z","article-title":"Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment","volume":"12","author":"Jin","year":"2022","journal-title":"Sci Rep"},{"key":"2025100305590775000_12.10.e009690.11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26790"},{"key":"2025100305590775000_12.10.e009690.12","doi-asserted-by":"crossref","first-page":"41242","DOI":"10.18632\/oncotarget.17168","article-title":"Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"2025100305590775000_12.10.e009690.13","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/s44321-024-00068-4","article-title":"TLR3 activation enhances abscopal effect of radiotherapy in HCC by promoting tumor ferroptosis","volume":"16","author":"Qiu","year":"2024","journal-title":"EMBO Mol Med"},{"key":"2025100305590775000_12.10.e009690.14","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1158\/2159-8290.CD-21-1022","article-title":"IFN\u03b1 Potentiates Anti\u2013PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment","volume":"12","author":"Hu","year":"2022","journal-title":"Cancer Discov"},{"key":"2025100305590775000_12.10.e009690.15","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2019.10.009","article-title":"A combination of check-point blockade and \u03b1-galactosylceramide elicits long-lasting suppressive effects on murine hepatoma cell growth in vivo","volume":"225","author":"Ishii","year":"2020","journal-title":"Immunobiology"},{"key":"2025100305590775000_12.10.e009690.16","doi-asserted-by":"publisher","DOI":"10.1177\/0023677215570086"},{"key":"2025100305590775000_12.10.e009690.17","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326259"},{"key":"2025100305590775000_12.10.e009690.18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jdermsci.2018.10.001","article-title":"Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma","volume":"93","author":"Kubo","year":"2019","journal-title":"J Dermatol Sci"},{"key":"2025100305590775000_12.10.e009690.19","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3182562d59"},{"key":"2025100305590775000_12.10.e009690.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00438-0"},{"key":"2025100305590775000_12.10.e009690.21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-844548"},{"key":"2025100305590775000_12.10.e009690.22","doi-asserted-by":"crossref","first-page":"107820","DOI":"10.1016\/j.lungcan.2024.107820","article-title":"Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer","volume":"192","author":"Felip","year":"2024","journal-title":"Lung Cancer (Auckl)"},{"key":"2025100305590775000_12.10.e009690.23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2024.101021","article-title":"A phase Ib\/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma","volume":"6","author":"Santoro","year":"2024","journal-title":"JHEP Rep"},{"key":"2025100305590775000_12.10.e009690.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"2025100305590775000_12.10.e009690.25","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919889001","article-title":"A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma","volume":"11","author":"Qin","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"2025100305590775000_12.10.e009690.26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Sig Transduct Target Ther"},{"key":"2025100305590775000_12.10.e009690.27","doi-asserted-by":"crossref","unstructured":"Khalaf AM , Fuentes D , Morshid AI , et al . . JHC 2018;Volume 5:61\u201373. 10.2147\/JHC.S156701","DOI":"10.2147\/JHC.S156701"},{"key":"2025100305590775000_12.10.e009690.28","doi-asserted-by":"crossref","first-page":"S1007","DOI":"10.1016\/j.annonc.2022.07.1120","article-title":"994P Efficacy and safety of capmatinib plus spartalizumab in treatment-na\u00efve patients with advanced NSCLC harboring MET exon 14 skipping mutation","volume":"33","author":"Wolf","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:59:17Z","timestamp":1759496357000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,30]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1136\/jitc-2024-009690"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009690","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}